1832 Asset Management
BXRX

1832 Asset Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

1832 Asset Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed -$1K – 893
2021
Q3 		$1K Hold
1
– – ﹤0.01% 843
2021
Q2 		$1K Buy
+1
New +$1.31K ﹤0.01% 723

Other funds holding BXRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AWA
Amplius Wealth Advisors Blue Bell, Pennsylvania $1.36B AUM 18.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

1832 Asset Management's BXRX Position: Q4 2021 in Review

1832 Asset Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2021, closing a stake of 1 share — an estimated $1K sold.

1832 Asset Management first reported a position in BXRX in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 28 funds tracked by Wall St. Rank hold BXRX as of Q4 2021.

  • 1832 Asset Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • 1832 Asset Management sold 1 Baudax Bio, Inc. Common Stock share in Q4 2021, an estimated $1K.
  • 1832 Asset Management first reported a position in Baudax Bio, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • 1832 Asset Management's Baudax Bio, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2021.

Based on 1832 Asset Management's 13F filing for Q4 2021, filed 15 Feb 2022.